MyMemory, la memoria di traduzione più grande del mondo
Click to expand

Coppia di lingue: Click to swap content  Argomento   
Chiedi a Google

Hai cercato: numbers    [ Disabilita i colori ]

Contributi umani

Da traduttori professionali, aziende, pagine web e banche di dati di traduzione disponibili al pubblico.

Aggiungi una traduzione

Indonesiano

Inglese

Dettagli

EnglishGolfer Name must be 4 to 16 characters in length, only letters and numbers allowed. Golfer Name can contain no spaces.

my mother cooks a delicious food

Ultimo aggiornamento: 2014-04-22
Frequenza d'uso: 1
Qualità:
Riferimento: Wikipedia

Golfer Name must be 4 to 16 characters in length, only letters and numbers allowed. Golfer Name can contain no spaces.

Golfer Name must be 4 to 16 characters in length, only letters and numbers allowed. Golfer Name can contain no spaces.

Ultimo aggiornamento: 2014-02-09
Argomento: Generico
Frequenza d'uso: 1
Qualità:
Riferimento: Anonimo

Rab,19 Des2012 pada 20:22 19 Des 2012 Pesan berbintang DARI לירז בסטיקר? KEPADA penerima CONGRATULATION, YOU WON THE SUM OF $400,000 (SEE MAIL FOR CLAIM) Tampilkan Detail Dari לירז בסטיקר? CONGRATULATIONS! CONGRATULATION!! CONGRATULATION!!! Dear Sir/ Madam, We are pleased to inform you of the lottery result winners of World Lotto Lottery Programme held today 18th December 2012 from the World lotto Lottery programme. Which is fully based on an electronic selection of all the internet user in Asia/ Europe/ Africa/ America. winners using e-mail addresses. You hereby have been approved a lump sum pay of US$400,000.00 (FOUR HUNDRED THOUSAND DOLLARS) ticket number: 47061725 serial number 7741137002 batch numbers : WNDLINC 70564943902. Ref: 4758961725 HOW TO CLAIM YOUR PRIZE : CONTACT MR RICHARD K.. LIORD EMAIL: claim_lotofflondon@live.com Please quote your reference, batch and winning number which can be found on the top left corner of this notification as well as with the following details below to enable the speedy evaluation and processing of your winning. 1 Your Name. 2 Your Home address. 3 Your Telephone number. 4 Your Age and occupation. 5 Ticket number. 6 Serial number. 7 File number. For security reasons, we advice all winners to REPLY to claim_lotofflondon@live.com and to keep this information confidential from the public until your claim is processed and your prize released to you. This is part of our security protocol to avoid double claiming and unwarranted taking advantage of this programme by non-participant or unofficial personnel. Note: All winnings MUST be claimed before the 18th January 2013, otherwise all funds will be forfeited. Congratulations once again on your winning! SIMPLY CONTACT YOUR AGENT FOR PAYMENT: claim_lotofflondon@live.com Sincerely, CARO SMITH Walla! Mail - Get your free unlimited mail today

Rab,19 Des2012 pada 20:22 19 Des 2012 Pesan berbintang DARI לירז בסטיקר? KEPADA penerima CONGRATULATION, YOU WON THE SUM OF $400,000 (SEE MAIL FOR CLAIM) Tampilkan Detail Dari לירז בסטיקר? CONGRATULATIONS! CONGRATULATION!! CONGRATULATION!!! Dear Sir/ Madam, We are pleased to inform you of the lottery result winners of World Lotto Lottery Programme held today 18th December 2012 from the World lotto Lottery programme. Which is fully based on an electronic selection of all the internet user in Asia/ Europe/ Africa/ America. winners using e-mail addresses. You hereby have been approved a lump sum pay of US$400,000.00 (FOUR HUNDRED THOUSAND DOLLARS) ticket number: 47061725 serial number 7741137002 batch numbers : WNDLINC 70564943902. Ref: 4758961725 HOW TO CLAIM YOUR PRIZE : CONTACT MR RICHARD K.. LIORD EMAIL: claim_lotofflondon@live.com Please quote your reference, batch and winning number which can be found on the top left corner of this notification as well as with the following details below to enable the speedy evaluation and processing of your winning. 1 Your Name. 2 Your Home address. 3 Your Telephone number. 4 Your Age and occupation. 5 Ticket number. 6 Serial number. 7 File number. For security reasons, we advice all winners to REPLY to claim_lotofflondon@live.com and to keep this information confidential from the public until your claim is processed and your prize released to you. This is part of our security protocol to avoid double claiming and unwarranted taking advantage of this programme by non-participant or unofficial personnel. Note: All winnings MUST be claimed before the 18th January 2013, otherwise all funds will be forfeited. Congratulations once again on your winning! SIMPLY CONTACT YOUR AGENT FOR PAYMENT: claim_lotofflondon@live.com Sincerely, CARO SMITH Walla! Mail - Get your free unlimited mail today

Ultimo aggiornamento: 2013-06-19
Argomento: Generico
Frequenza d'uso: 1
Qualità:
Riferimento: Anonimo

gAssessment of menopausal status, including premature ovarian failure Assessing ovarian status, including follicle development, ovarian reserve, and ovarian responsiveness, as part of an evaluation for infertility and assisted reproduction protocols such as in vitro fertilization Assessing ovarian function in patients with polycystic ovarian syndrome Evaluation of infants with ambiguous genitalia and other intersex conditions Evaluating testicular function in infants and children Diagnosing and monitoring patients with antimullerian hormone-secreting ovarian granulosa cell tumors Method Name Immunometric Assay Reporting Name Antimullerian Hormone, S Aliases Mullerian inhibiting factor (MIF) Mullerian-inhibiting hormone (MIH) Mullerian-inhibiting substance (MIS) Specimen Type Serum Specimen Required Container/Tube: Preferred: Red top Acceptable: Serum gel Specimen Volume: 0.2 mL Specimen Minimum Volume 0.1 mL Reject Due To Hemolysis Mild OK; Gross reject acceptable to 1,000 mg/dL Lipemia Mild OK, Gross needs to be spun Icterus Mild OK, interpret with caution; Gross reject Other NA Specimen Stability Information Specimen Type Temperature Time Serum Refrigerated (preferred) 7 days Frozen 90 days Clinical Information Antimullerian hormone (AMH), also known as mullerian-inhibiting substance, is a dimeric glycoprotein hormone belonging to the transforming growth factor-beta family. It is produced by Sertoli cells of the testis in males and by ovarian granulosa cells in females. Expression during male fetal development prevents the mullerian ducts from developing into the uterus and other mullerian structures, resulting in normal development of the male reproductive tract. In the absence of AMH, the mullerian ducts and structures develop into the female reproductive tract. AMH is also expressed in the follicles of females of reproductive age and inhibits the transition of follicles from primordial to primary stages. Follicular AMH production begins during the primary stage, peaks in the preantral and small antral stages, and then decreases to undetectable concentrations as follicles grow larger. AMH serum concentrations are elevated in males under 2 years old and then progressively decrease until puberty, when there is a sharp decline. By contrast, AMH concentrations are low in female children until puberty. Concentrations then decline slowly over the reproductive lifespan as the size of the pool of remaining microscopic follicles decreases. AMH concentrations are frequently below the detection limit of current assays after natural or premature menopause. Because of the gender differences in AMH concentrations, its changes in circulating concentrations with sexual development, and its specificity for Sertoli and granulosa cells, measurement of AMH has utility in the assessment of gender, gonadal function, fertility, and as a gonadal tumor marker. Since AMH is produced continuously in the granulosa cells of small follicles during the menstrual cycle, it is superior to the episodically released gonadotropins and ovarian steroids as a marker of ovarian reserve. Furthermore, AMH concentrations are unaffected by pregnancy or use of oral or vaginal estrogen- or progestin-based contraceptives. Studies in fertility clinics have shown that females with higher concentrations of AMH have a better response to ovarian stimulation and tend to produce more retrievable oocytes than females with low or undetectable AMH. Females at risk of ovarian hyperstimulation syndrome after gonadotropin administration can have significantly elevated AMH concentrations. Polycystic ovarian syndrome can elevate serum AMH concentrations because it is associated with the presence of large numbers of small follicles. AMH measurements are commonly used to evaluate testicular presence and function in infants with intersex conditions or ambiguous genitalia, and to distinguish between cryptorchidism (testicles present but not palpable) and anorchia (testicles absent) in males. In minimally virilized phenotypic females, AMH helps differentiate between gonadal and nongonadal causes of virilization. Serum AMH concentrations are increased in some patients with ovarian granulosa cell tumors, which comprise approximately 10%[ERROR] of ovarian tumors. AMH, along with related tests including inhibin A and B (#81049 Inhibin A, Tumor Marker, Serum; #88722 Inhibin B, Serum, #86336 Inhibin A and B, Tumor Marker, Serum), estradiol (#81816 Estradiol, Serum), and CA-125 (#9289 Cancer Antigen 125 (CA 125), Serum), can be useful for diagnosing and monitoring these patients. Reference Values Males 12 years: 0.7-19 ng/mL Females 45 years: <1.0 ng/mL Interpretation Menopausal women or women with premature ovarian failure of any cause, including after cancer chemotherapy, have very low antimullerian hormone (AMH) levels, often below the current assay detection limit of 0.25 ng/mL. While the optimal AMH concentrations for predicting response to in vitro fertilization are still being established, it is accepted that AMH concentrations in the perimenopausal to menopausal range (0-0.6 ng/mL) indicate minimal to absent ovarian reserve. Depending on patient age, ovarian stimulation is likely to fail in such patients and most fertility specialists would recommend going the donor oocyte route. By contrast, if serum AMH concentrations exceed 3 ng/mL, hyper-response to ovarian stimulation may result. For these patients, a minimal stimulation would be recommended. In patients with polycystic ovarian syndrome, AMH concentrations may be 2 to 5 fold higher than age-appropriate reference range values. Such high levels predict anovulatory and irregular cycles. In children with intersex conditions, an AMH result above the normal female range is predictive of the presence of testicular tissue, while an undetectable value suggests its absence. In boys with cryptorchidism, a measurable AMH concentration is predictive of undescended testes, while an undetectable value is highly suggestive of anorchia or functional failure of the abnormally sited gonad. Granulosa cell tumors of the ovary may secrete AMH, inhibin A, and inhibin B. Elevated levels of any of these markers can indicate the presence of such a neoplasm in a woman with an ovarian mass. Levels should fall with successful treatment. Rising levels indicate tumor recurrence/progression. Cautions Like all laboratory tests, antimullerian hormone (AMH) measurement alone is seldom sufficient for diagnosis and results should be interpreted in the light of clinical findings and other relevant test results, such as ovarian ultrasonography (in fertility applications, this would include an antral follicle count), abdominal or testicular ultrasound (intersex/testicular function applications) and measurements of sex steroids (estradiol, testosterone, progesterone), follicle-stimulating hormone (FSH), inhibin B (for fertility), and inhibin A and B (for tumor workup). Elevated AMH is not specific for malignancy, and the assay should not be used exclusively to diagnose or exclude an AMH-secreting ovarian tumor. This assay demonstrates no cross reactivity with transforming growth factor beta-1, activin A, inhibin A or B, luteinizing hormone alpha or beta, FSH, thyroid-stimulating hormone, or insulin-like growth factor-1. However, although unlikely, there might be cytokines that have not been evaluated for cross reactivity that do cross react, resulting in false-elevations. As with other immunoassays, the AMH assay can be susceptible to false-low results at extremely high analyte concentrations (hooking effect) or in the hypothetical scenario of the presence of anti-AMH autoantibodies in a patient serum specimen. Heterophilic antibody interferences that are not blocked by the assay’s blocking regents may also rarely occur, causing typically false-high results. If test results are incongruent with the clinical picture, the laboratory should be contacted.

Indonesian translation google english

Ultimo aggiornamento: 2013-04-16
Argomento: Generico
Frequenza d'uso: 1
Qualità:
Riferimento: Anonimo
Avvertenza: Contiene formattazione HTML non visibile

Aggiungi una traduzione